Infliximab in Russian clinical practice

Infliximab in Russian clinical practice

The study of infliximab began (INF) in Russia in 2001. It was the first genetically engineered biological agent (GEBA) registered in our country to treat patients with rheumatoid arthritis (RA). With the advent of infliximab, a Russian biological rheumatoid arthritis therapy registry started its wor...

Full description

Saved in:
Bibliographic Details
Main Authors: G V Lukina, Ya A Sigidin, E S Pozdnyakova, E N Aleksandrova, A A Novikov, A V Smirnov, S I Glukhova, E L Nasonov
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2012-09-01
Series:Современная ревматология
Subjects:
rheumatoid arthritis
genetically engineered biological agents
infliximab
russian biological rheumatoid arthritis therapy registry
Online Access:https://mrj.ima-press.net/mrj/article/view/429
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items